Sacha Choupa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sacha Choupa has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Amy Luo
Bloomberg School of Public Health Johns Hopkins University Baltimore Maryland USA
1 shared publication- Ann Kinga Malinowski
Department of Obstetrics and Gynecology, Department of Health Research Methods Evidence and Impact McMaster University Hamilton Ontario Canada
1 shared publication - Gloria Frances Gerber
Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
1 shared publication - Jayla Lynn Scott
Division of Hematology, Department of Medicine Johns Hopkins University Baltimore Maryland USA
1 shared publication - Kevin H. M. Kuo
Division of Haematology, Department of Medicine University Health Network Toronto Ontario Canada
1 shared publication - Lydia H. Pecker
Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD
1 shared publication
Latest Publications
- 16 November 2026
- Published by Wiley in British Journal of Haematology
Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease
Summary: Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.
- 16 November 2026
- Published by Wiley in British Journal of Haematology
Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease
Summary: Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.